Please login to the form below

Not currently logged in
Email:
Password:

YM BioSciences

This page shows the latest YM BioSciences news and features for those working in and with pharma, biotech and healthcare.

Baxter and CTI's Jakafi rival clears phase III trial

Baxter and CTI's Jakafi rival clears phase III trial

Other JAK2 inhibitors coming through the pipeline for myelofibrosis include Gilead Sciences' CYT387, which it acquired as part of its $510m takeover of YM Biosciences at the end of 2012.

Latest news

  • Jakafi cleared for bone marrow disorder by FDA Jakafi cleared for bone marrow disorder by FDA

    Other JAK inhibitors coming through the pipeline include Gilead Sciences' CYT387, acquired as part of its $510m takeover of YM Biosciences at the end of 2012 and Cell Therapeutics/Baxter's

  • Gilead expands in cancer with $510m YM BioSciences deal Gilead expands in cancer with $510m YM BioSciences deal

    Gilead expands in cancer with $510m YM BioSciences deal. Lands JAK inhibitor CYT387. ... Gilead Sciences has developed its emerging oncology pipeline with a $510m offer to buy Canada's YM Biosciences, including lead product CYT387 for haematological

  • ASH meeting hears of progress with myelofibrosis drugs ASH meeting hears of progress with myelofibrosis drugs

    Another company developing JAK inhibitor for myelofibrosis - YM Biosciences - reported phase I/II data at ASH for its candidate CYT387. ... YM Biosciences has suggested CYT387 may be less likely to exacerbate anaemia than Jakafi, although this requires

  • Feverish activity

    CIMYM (a subsidiary of YM BioSciences) is developing nimotuzumab (TheraCIM h-R3, Theraloc), an EGFR antagonist with the intent of blocking epithelial growth factor and tumour growth factor from binding to ... Another media release from YM BioSciences, in

  • Battling breast cancer

    YM Biosciences' tesmilifene is a histamine antagonist in phase III trials, which has been granted fast track status by the FDA for enhancing the activity of anthracycline chemotherapy in the treatment

More from news
Approximately 1 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cuttsy + Cuttsy

How do you understand what patients really need, without actually living their lives? How do you walk in someone else’s...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics